Biliary tract carcinomas: from chemotherapy to targeted therapy.
about
Gemcitabine-based chemotherapy for advanced biliary tract carcinomasCapecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer.Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract CancerMolecular Targets in Biliary Carcinogenesis and Implications for Therapy.Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy.The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy.AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines.Molecular targeted therapy for biliary tract malignancy: defining the target.Targeted agents: how can we improve the outcome in biliary tract cancer?Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer.Down-regulation of FoxM1 inhibits viability and invasion of gallbladder carcinoma cells, partially dependent on inducement of cellular senescenceBiliary cancer: Utility of next-generation sequencing for clinical management.Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection.Emerging drugs for biliary cancer.
P2860
Q24187573-98E9F200-79EB-4E6B-81A7-48CA41EEBB85Q33428348-8D27EBC6-DF22-4719-AEBB-AC6D33CEF4A4Q33555296-D54C86D3-556D-45F4-BB72-997BFB9867B5Q34898364-94588D9A-EEC7-4625-883D-2FE14F9A3104Q35017050-2DBB4D36-D8D7-4B10-BE77-30725E8166A7Q35150642-F1A92E96-B759-435E-96A0-C558FBFAA85FQ35820533-B5CBD3E0-EDE4-46C4-B587-F4A889742779Q36278688-5595C273-54BC-45A0-A07F-7589E948BCA3Q36785251-401924AF-10AB-417A-BE83-5EEE670FA03DQ37225342-0B17F241-9126-4040-BF80-75510AFED962Q37584574-DD42B2F2-D6B4-44CA-B225-3D6BBA2D0B3EQ37584590-082C02B7-C095-47C4-A589-3D6E67A7963CQ37588461-CA6E09C7-2623-42D3-891E-F8882B49F290Q38701620-B33D8ADD-C850-4121-A96B-B35DFABB07C9Q38970720-F0D626A0-1001-40C6-A589-FFFFCE0B3268Q39396785-1171C739-0AB0-4B4A-9CE4-50734DAA340FQ40352514-EE5AC1AF-9576-4961-8657-1234D4D30993Q44965723-F8CE0A6E-F234-4BB3-8DA9-9F1E25E59CB3Q51327505-BC01BF8D-151B-4A88-9ED2-101E34AD71E5
P2860
Biliary tract carcinomas: from chemotherapy to targeted therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biliary tract carcinomas: from chemotherapy to targeted therapy.
@en
type
label
Biliary tract carcinomas: from chemotherapy to targeted therapy.
@en
prefLabel
Biliary tract carcinomas: from chemotherapy to targeted therapy.
@en
P50
P1476
Biliary tract carcinomas: from chemotherapy to targeted therapy
@en
P2093
Francesco Leone
P304
P356
10.1016/J.CRITREVONC.2012.06.006
P577
2012-07-17T00:00:00Z